S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
"This Could be the Biggest Stock Story of 2023" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
New Breakthrough "Living Software" Has Been… (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
"This Could be the Biggest Stock Story of 2023" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
New Breakthrough "Living Software" Has Been… (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
"This Could be the Biggest Stock Story of 2023" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
New Breakthrough "Living Software" Has Been… (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
"This Could be the Biggest Stock Story of 2023" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
New Breakthrough "Living Software" Has Been… (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NASDAQ:ROIV

Roivant Sciences (ROIV) Stock Forecast, Price & News

$10.33
+0.11 (+1.08%)
(As of 09/22/2023 ET)
Compare
Today's Range
$10.06
$10.44
50-Day Range
$10.22
$12.60
52-Week Range
$2.87
$12.84
Volume
4.72 million shs
Average Volume
4.27 million shs
Market Capitalization
$7.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.75

Roivant Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
42.8% Upside
$14.75 Price Target
Short Interest
Bearish
4.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.14mentions of Roivant Sciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$8.32 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.06) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

719th out of 963 stocks

Pharmaceutical Preparations Industry

334th out of 458 stocks


ROIV stock logo

About Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

ROIV Price History

ROIV Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Skin In The Game: Behind Roivant's Significant Rise
The Brash Strategy That Made Vivek Ramaswamy a Fortune
Roivant Sciences (NASDAQ: ROIV)
What 9 Analyst Ratings Have To Say About Roivant Sciences
See More Headlines
Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

ROIV Company Calendar

Last Earnings
8/14/2023
Today
9/24/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ROIV
Fax
N/A
Employees
904
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.75
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+42.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-1,009,030,000.00
Net Margins
-1,233.11%
Pretax Margin
-1,528.46%

Debt

Sales & Book Value

Annual Sales
$61.28 million
Book Value
$2.11 per share

Miscellaneous

Free Float
736,242,000
Market Cap
$7.97 billion
Optionable
Not Optionable
Beta
1.28
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Matthew Gline (Age 39)
    CEO & Director
    Comp: $1.77M
  • Dr. Eric Venker M.D. (Age 36)
    Pharm.D., Pres & COO
    Comp: $1.28M
  • Dr. Mayukh Sukhatme M.D. (Age 47)
    Pres & Chief Investment Officer
    Comp: $1.72M
  • Mr. Richard Pulik (Age 43)
    Chief Financial Officer
  • Ms. Rakhi KumarMs. Rakhi Kumar (Age 43)
    Chief Accounting Officer
  • Dr. Huafeng Xu Ph.D.
    Chief Technology Officer
  • Mr. Josh Chen
    Gen. Counsel
  • Ms. Kelly Graff
    Head of People
  • Ms. Marianne L. Romeo (Age 55)
    Head of Global Transactions & Risk Management
  • Mr. Alex Gasner
    Exec. VP of Roivant Health













ROIV Stock - Frequently Asked Questions

Should I buy or sell Roivant Sciences stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ROIV shares.
View ROIV analyst ratings
or view top-rated stocks.

What is Roivant Sciences' stock price forecast for 2023?

8 analysts have issued twelve-month price targets for Roivant Sciences' shares. Their ROIV share price forecasts range from $10.00 to $23.00. On average, they anticipate the company's share price to reach $14.75 in the next twelve months. This suggests a possible upside of 42.8% from the stock's current price.
View analysts price targets for ROIV
or view top-rated stocks among Wall Street analysts.

How have ROIV shares performed in 2023?

Roivant Sciences' stock was trading at $7.99 at the start of the year. Since then, ROIV shares have increased by 29.3% and is now trading at $10.33.
View the best growth stocks for 2023 here
.

When is Roivant Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ROIV earnings forecast
.

How were Roivant Sciences' earnings last quarter?

Roivant Sciences Ltd. (NASDAQ:ROIV) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.10. The business had revenue of $21.60 million for the quarter, compared to analyst estimates of $24.49 million. Roivant Sciences had a negative trailing twelve-month return on equity of 73.68% and a negative net margin of 1,233.11%. The company's revenue for the quarter was up 402.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.48) earnings per share.

What is Roivant Sciences' stock symbol?

Roivant Sciences trades on the NASDAQ under the ticker symbol "ROIV."

Who are Roivant Sciences' major shareholders?

Roivant Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Patient Square Capital LP (1.65%), BlackRock Inc. (1.61%), State Street Corp (1.24%), Woodline Partners LP (0.50%), Rubric Capital Management LP (0.46%) and Perceptive Advisors LLC (0.41%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Global Investors Lp Viking, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy.
View institutional ownership trends
.

How do I buy shares of Roivant Sciences?

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Roivant Sciences' stock price today?

One share of ROIV stock can currently be purchased for approximately $10.33.

How much money does Roivant Sciences make?

Roivant Sciences (NASDAQ:ROIV) has a market capitalization of $7.97 billion and generates $61.28 million in revenue each year. The company earns $-1,009,030,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How many employees does Roivant Sciences have?

The company employs 904 workers across the globe.

How can I contact Roivant Sciences?

Roivant Sciences' mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The official website for the company is roivant.com. The company can be reached via phone at 44-20-7400-3347.

This page (NASDAQ:ROIV) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -